Orexigen files obesity drug Contrave with US FDA
This article was originally published in Scrip
Executive Summary
Orexigen Therapeutics has submitted its obesity drug Contrave (naltrexone SR plus bupropion SR) in the US. As such, Contrave trails around three months behind two other obesity drugs, Arena's lorcaserin and Vivus's Qnexa (phentermine and topiramate), that were submitted to the FDA in December last year.